Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2025 07:30 ET | Source: Vyluma, Inc.

Vyluma Announces Acceptance of Drug Application for NVK002 by China’s National Medical Products Administration (NMPA)

Vyluma Announces NVK002 Drug Application Acceptance in China
June 18, 2024 07:30 ET | Source: Vyluma, Inc.

Vyluma Meets with FDA on Atropine Sulfate Ophthalmic Solution 0.01% Under Development to Treat Pediatric Myopia

Vyluma Discusses Response to FDA’s Questions and Clarifies Regulatory Pathway for its 505(b)(2) NDA, NVK002 to slow the progression of myopia in children.
May 29, 2024 07:30 ET | Source: Vyluma, Inc.

Vyluma Announces Marketing Authorization Application Validation for the European Union

Vyluma announces Marketing Authorisation Application (MAA) validation for the EU for NVK002 to slow the progression of pediatric myopia.
October 11, 2023 07:00 ET | Source: Vyluma, Inc.

Vyluma Announces Positive Results From Second Stage of Phase III CHAMP Study of NVK002 for the Treatment of Myopia in Children

BRIDGEWATER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today positive...
June 06, 2023 07:00 ET | Source: Vyluma, Inc.

Vyluma Announces FDA Acceptance of New Drug Application for NVK002, Its Novel Investigational Treatment for Pediatric Myopia

BRIDGEWATER, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- June 6, 2023 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced...
January 05, 2023 07:00 ET | Source: Vyluma, Inc.

Vyluma to Present at the 41st Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, today announced it...
October 27, 2022 12:00 ET | Source: Vyluma, Inc.

Vyluma Announces Positive Results From Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in Children

BRIDGEWATER, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, today announced top-line...
September 01, 2022 07:00 ET | Source: Vyluma, Inc.

Vyluma Completes Last Patient Visit for Primary Analysis of Pivotal Phase III CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Children

BRIDGEWATER, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today that the...